問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Taichung Veterans General Hospital

Link to Hospital

  • 1,624

    Total Beds

  • 934

    Total Doctors

  • tcvghcrc@vghtc.gov.tw
  • Clinical Research Center
  • 04-23592525#4780
  • 407Taichung CityTaichung Xitun1650 Taiwan Boulevard Sect. 4, Taichung, Taiwan 407219, ROC

Recruiting Trial

576Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1334Cases

2018-04-13 - 2022-04-13

Phase II

A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

  • Condition/Disease

    Advanced Non-Small Cell Lung Carcinoma

  • Test Drug

    REGN2810

Participate Sites
5Sites

Terminated5Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-02-01 - 2016-12-31

Phase III

A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate to Very Severe COPD, Compared with Placeb

  • Condition/Disease

    COPD

  • Test Drug

    Glycopyrronium and Fomoterol Fumarate Inhalation Aerosol

Participate Sites
6Sites

Terminated5Sites

杭良文
China Medical University Hospital-Taipei

未分科

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

2017-09-01 - 2019-10-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

  • Condition/Disease

    Hospital-acquired Bacterial Pneumonia, Ventilator-associatedBacterial Pneumonia, or Healthcare-associated BacterialPneumonia Caused by Gram-negative Pathogens

  • Test Drug

    S-649266

Participate Sites
4Sites

Terminated4Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2010-09-01 - 2013-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-04-01 - 2010-05-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-01-01 - 2019-05-31

Phase III

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

  • Condition/Disease

    uncontrolled severe asthma

  • Test Drug

    QAW039

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

許武輝醫師
China Medical University Hospital

Division of Thoracic Medicine

2015-08-14 - 2017-12-31

Phase II

A multicenter, randomized, double-blind, placebo and active controlled Phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU)

  • Condition/Disease

    Chronic Spontaneous Urticaria (CSU)

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

2017-11-30 - 2019-12-30

Phase II

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  • Condition/Disease

    Primary IgA Nephropathy

  • Test Drug

    LNP023

Participate Sites
4Sites

Terminated4Sites

吳麥斯
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

2017-05-01 - 2020-03-04

Phase II

A randomized, double blind, placebo controlled multicenter Phase 2 doseranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s syndrome

  • Condition/Disease

    Sjögren’s syndrome

  • Test Drug

    VAY736

Participate Sites
7Sites

Terminated5Sites

藍忠亮
China Medical University Hospital

藍忠亮
China Medical University Hospital-Taipei

未分科

1 117 118 119 120 121 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB